Ramipril Reduces Risk of Stroke and Other Cerebrovascular Events – Altace
(American College of Cardiology) Results of a randomized placebo-controlled trial showed that the use of ramipril (Altace), but not vitamin E, reduces the risk of stroke and other cerebrovascular events in patients by about one-third in both primary and secondary prevention as well as among patients with or without hypertension. A total of 9,451 high-risk patients who were at least 55 years of age and had either previous cardiovascular disease or diabetes plus one risk factor were randomized to receive ramipril (up to 10 mg per day) or placebo, and vitamin E (400 IU per day) or placebo, for a mean of 4.5 years. Ramipril reduced the risk of strokes, transient ischemic stroke and carotid endarterectomy. Ramipril was similarly effective in reducing the risk of a stroke among patients with or without previous cerebrovascular disease. Vitamin E did not reduce the risk of fatal or nonfatal stroke.–JACKIE BOSCH, MSC, ET AL., McMaster University, Hamilton, Canada.
COPYRIGHT 2000 American Academy of Family Physicians
COPYRIGHT 2000 Gale Group